Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites

ConclusionsTolvaptan significantly increased urine volumes similarly in patients with s-CKD and n-CKD without affecting renal function. As responders achieved a better prognosis, tolvaptan could be a good option to treat ascites in patients with cirrhosis and s-CKD.

http://link.springer.com/10.1007/s40261-018-0714-5

Source: Clinical Drug Investigation - October 4, 2018 Category: Drugs & Pharmacology Source Type: research